Why the Geography of Your CDMO Partner Matters
The choice to develop a drug in Europe rather than the United States is not just a matter of geography. It affects your regulatory strategy, your manufacturing standards, the reference points in your CMC dossier, and ultimately the timeline to your first clinical data. For many biotech companies, particularly those seeking approval in both markets, understanding the interplay between EMA and FDA requirements from the outset saves significant rework later.
Key Regulatory Differences: EMA vs. FDA
| Regulatory Element | EMA (European) | FDA (United States) |
| Pre-clinical to Phase I submission | IMPD (Investigational Medicinal Product Dossier) in CTD format | IND (Investigational New Drug application) |
| GMP standard | EU GMP (EudraLex Vol 4) | cGMP (21 CFR Parts 210/211) |
| Regulatory inspection framework | National Competent Authorities + EMA | FDA CDER/CBER inspection |
| CMC data expectations at Phase I | Pragmatic; fit-for-purpose with defined limitations | Similar; FDA responsive to first-cycle CMC deficiency letters |
| Paediatric obligation | Paediatric Investigation Plan (PIP) required | Paediatric Study Plan (PSP) under PREA |
| Advanced therapy products | ATMP Regulation (1394/2007), CAT committee | BLA/NDA process through CBER |
| Clinical trial authorisation | Single CTA per Member State or EU CTA (CTIS) | IND filing covers US clinical sites |
The Advantages of Developing in Europe
EU GMP Is Recognised Globally
EU GMP certification is accepted by a wide range of health authorities beyond Europe, including those of Australia, Canada, Japan, and many emerging markets. Developing under EU GMP from the outset means your manufacturing data is audit-ready for more markets without additional inspection overhead. The EU GMP mutual recognition agreements with the FDA and other agencies further reduce duplication for globally-focused programmes.
Parallel IMPD/IND Submissions Are Achievable
For companies targeting both EU and US clinical trials, a well-structured CMC dossier developed in Europe can form the basis of both an IMPD and an IND submission. The CTD format (Common Technical Document) was designed precisely to enable this, with Module 3 quality data common to both applications. A CDMO with experience in dual submissions can build that efficiency into the development plan from the start.
Cost-Effective Early Development
For pre-clinical and Phase I work, European CDMOs often offer highly competitive pricing relative to comparable US facilities, with equivalent or superior scientific capabilities. For a capital-efficient biotech, that cost advantage at the development stage can meaningfully extend the runway to the next funding milestone.
How Ardena Supports Multi-Jurisdictional Programmes
Ardena’s facilities are authorised under EU GMP and operate within regulatory environments that are routinely inspected by national competent authorities across Belgium, the Netherlands, Spain, and the US FDA. The organisation has experience preparing CMC sections for both IMPD and IND submissions, and can advise on where regulatory strategies diverge between jurisdictions.
For programmes seeking to run EU and US trials in parallel, Ardena’s regulatory team can help structure the CMC development plan to produce data that satisfies both agencies without duplicating the experimental work
